Addressing Racial Disparities in Health Care
Latest News
CAR T-Cell Therapy is a ‘Revolution in Cancer Immunotherapy’
Chimeric antigen receptor (CAR) T-cell therapy is "paradigm changing" -- a "revolution in cancer immunotherapy." This treatment has ushered in a new era of therapy for blood cancer patients.
Learn MoreTo Treat Ovarian Cancer With PARP Inhibitors or Not: Factoring the Progression-Free Survival Benefit and Side Effects Into the Decision
PARP inhibitors like niraparib (Zejula) are an effective tool against ovarian cancer. The NOVA trial established that niraparib as maintenance therapy in platinum-sensitive patients significantly improved progression-free survival compared to placebo, regardless of women's BRCA or homologous recombination deficiency (HRD) status. Then, the PRIMA study found the treatment extended PFS in patients with newly diagnosed ovarian cancer, with or without HRD deficiency.
Learn MoreCAR T-Cell Therapy is ‘Exciting,’ But Also ‘Overwhelming’ for Patients
Chimeric antigen receptor (CAR) T-cell therapy has been transformative in blood cancer therapy, particularly for patients with previously poor outcomes; however, producing the CAR T cells can be a complex process.
Learn MorePatients Need Careful Monitoring for CAR T-Cell Therapy Side Effects
Chimeric antigen receptor (CAR) T-cell therapy has become a major ally in the treatment of certain lymphomas and leukemias. However, this therapy is not without risks.
Learn MoreThe Promise of CAR T-Cell Therapy for Multiple Myeloma
Chimeric antigen receptor (CAR) T-cell therapy is showing great promise in multiple myeloma, with response rates in studies of 85% or more, and about half of patients going into complete remission for a year or longer.
Learn MoreCytokine Release Syndrome: The Downside of CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has had great success thus far, producing lasting responses and even remissions in patients with relapsed or refractory hematologic cancers such as B-cell lymphoma and acute lymphoblastic leukemia (ALL).
Learn MorePARP Inhibitors Boost Survival in Ovarian Cancer, Prompting New ASCO Guidelines on Their Use
PARP inhibitors are a class of drugs that inhibit one of the backup systems of DNA damage repair. Ovarian cancers with BRCA1, BRCA2, or certain other mutations have a defect in a major DNA damage repair pathway and are highly dependent on secondary pathways for their survival.
Learn MoreDelaying Treatment to Protect Ovarian Cancer Patients from COVID Has Benefits and Risks
Determining the most appropriate cancer treatment for your patients usually involves finding a delicate balance between the risks and benefits. How effective will the treatment be? Can a patient tolerate it? COVID adds one more factor into the equation.
Learn More